Navigation Links
FDA Approves Label Update for PREZISTA® to Include 192-Week Data in HIV-1-Infected Adult Patients Starting Treatment
Date:10/21/2011

TITUSVILLE, N.J., Oct. 21, 2011 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for PREZISTA® (darunavir) tablets to include 192-week data from the ARTEMIS study.  ARTEMIS evaluated the efficacy and safety of PREZISTA with ritonavir (r) vs. lopinavir/r in combination with other antiretrovirals (ARVs) for the treatment of human immunodeficiency virus (HIV-1) in treatment-naive patients.

"Since its launch in 2006, PREZISTA has become one of the most prescribed antiretroviral agents in the protease inhibitor class.  Having data showing the efficacy, safety, and tolerability of PREZISTA over 192 weeks should give added confidence to healthcare providers who are considering PREZISTA as an option for their patients who are starting treatment for the first time," said Vanessa Broadhurst, President, Janssen Therapeutics.

PREZISTA was developed by Tibotec Pharmaceuticals and is marketed in the U.S. by Janssen Therapeutics. PREZISTA, co-administered with ritonavir (PREZISTA/ritonavir), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection.

This indication is based on analyses of plasma HIV-1 RNA levels and CD4+ cell counts from two controlled Phase 3 trials of 48 weeks duration in antiretroviral treatment-naive and treatment experienced patients and two controlled Phase 2 trials of 96 weeks duration in clinically advanced, treatment-experienced adult patients.

In treatment-experienced adult patients, the following points should be considered when initiating therapy with PREZISTA/r:

  • Treatment history and, when available, genotypic or phenotypic testing should guide the use of PREZISTA/r.
  • The use of other active agents with PREZISTA/r is associated with a greater likelihood of treatment response.

  • ARTEMIS 192-Week Study
    '/>"/>

    SOURCE Janssen Therapeutics, Division of Janssen Products, LP
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body
    2. FDA Approves Combination Therapy Juvisync
    3. FDA Approves Cialis to Treat Benign Prostatic Hyperplasia
    4. FDA Approves Remicade to Treat Ulcerative Colitis in Children Older Than 6 Years
    5. FDA Approves Soliris for Rare Pediatric Blood Disorder
    6. FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
    7. FDA Approves Xalkori with Companion Diagnostic for a Type of Late-stage Lung Cancer
    8. FDA Approves Firazyr To Treat Acute Attacks of Hereditary Angioedema
    9. FDA Approves Adcetris to Treat Two Types of Lymphoma
    10. FDA Approves the First Specific Treatment for Scorpion Stings
    11. Cardinal Health Board of Directors Approves Cash Dividend, Elects David P. King as Director
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/30/2015)... LONDON , June 30, 2015 ... Street issued a survey to Rosacea sufferers as part of ... what treatments Rosacea sufferers found effective for their Rosacea. The ... age, and comprised 47% men and 53% women. ... of survey participants did not consider or attempt to visit ...
    (Date:6/30/2015)... June 30, 2015 First Choice Wellness Care ... Astanza Duality and is the only clinic in the ... tattoo removal treatments. The practice has recently expanded their ... brand to showcase their focus in the procedure. They ... results, faster ink clearance, and superior service. ...
    (Date:6/30/2015)... June 30, 2015  Avanir Pharmaceuticals, Inc. today ... showing that treatment with NUEDEXTA ® was ... of pseudobulbar affect (PBA) in patients with traumatic ... distressing condition characterized by sudden and uncontrollable outbursts ... diseases or brain injury. PRISM II is a ...
    Breaking Medicine Technology:84% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 2First Choice Wellness Care Becomes Tallahassee Leader In Tattoo Removal With Astanza Duality 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 2Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 3Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 4Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 5Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 6Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II Study 7
    ... Top-line Data Expected in August -, EXTON, ... today the completion of the pivotal efficacy portion ... Isolagen,Therapy(TM) for the treatment of nasolabial folds, or ... the primary efficacy follow-up visit,and collation of this ...
    ... ... Professionals, VOORHEES, N.J., July 1 ... a wide spectrum of,severity, ranging from mild diarrhea to pseudomembranous colitis ... who develop an initial,case of CDI.(1) These patients are at increased ...
    Cached Medicine Technology:Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles 2Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles 3Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease 2
    (Date:6/30/2015)... ... June 30, 2015 , ... CCAR is pleased to announce its ... in Hartford, Willimantic and Bridgeport. This month, staff member Jim Higgins left his ... He is excited to take on this role of organizing peer recovery support ...
    (Date:6/30/2015)... Los Angeles, CA (PRWEB) , ... June 30, ... ... Physicians News Digest discussed the advantages that fat transfer procedures had ... breast reconstruction using fat transfer techniques create breasts that “look and feel natural,” ...
    (Date:6/30/2015)... GA (PRWEB) , ... June 30, 2015 , ... After ... by the U.S. Food and Drug Administration, GlobalSun (TM) — sunscreen specifically formulated for ... with an SPF rating of 35, hits the market just in time to help ...
    (Date:6/30/2015)... ... June 30, 2015 , ... ... response profiling test to help oncologists provide personalized cancer treatment, will be ... assay provides the oncologist with valuable insight on how a specific patient’s ...
    (Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... medical device market research, has launched a new reimbursement insurance policy tracking and ... professionals to receive US insurance policy and rate updates in real-time from hundreds ...
    Breaking Medicine News(10 mins):Health News:The Connecticut Community for Addiction Recovery takes Recovery Coaching to a new level 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 2Health News:Recent Article Advocating for Breast Reconstruction with Fat Transfers Successfully Outlines the Advantages of Transfer Procedures, Notes Beverly Hills Physicians 3Health News:GlobalSun – The First Sunscreen Developed for All People of Color – Hits The Market 2Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 2Health News:Correct Chemo Joins NextGxDx Online Genetic Testing Marketplace 3Health News:iData Research Introduces New Medical Insurance Reimbursement Policy & Rate Tracker Subscription Service 2
    ... Fla., Jan. 7 - 3M, in,partnership with Roush Fenway Racing, ... paint scheme to the American Red Cross for two races,during ... space on the,rear side panel of the car where the ... year., (Photo: http://www.newscom.com/cgi-bin/prnh/20080107/DC10974 ), "This is ...
    ... WellPoint, Inc. (NYSE: WLP ) today,announced that ... Technology,and Government Services Business Unit, has been recognized ... Computerworld,s 2008 Premier 100 honors the 100 ... and motivating employees; envisioning,innovative solutions to business challenges; ...
    ... 7 Barc, the leader in the $1.8 billion,African-American ... of its new travel size for its market leading ... product is now available,in a convenient 1.7 oz bottle ... reduces irritation and ingrown hairs due to shaving,preventing new ...
    ... cells and cancer stem cells reveals that the cancer ... of development. The research, published by Cell Press in ... understanding of glioma pathophysiology and provides new directions for ... types of tumors. , Tumor-initiating cells with stem like ...
    ... COLUMBUS , Ohio New research suggests that at any ... (EMTs) and paramedics in the United States miss work because ... , A study examining how common these injuries are and ... professionals also suggests that in one year, an estimated 8.1 ...
    ... less food had same effect on weight at age 2, study ... toddlers consume, either by trying to get them to eat less ... weight by the age of 2, new British research suggests. , ... always in the best interest of a young child, according to ...
    Cached Medicine News:Health News:3M Donates Two Full Paint Schemes to American Red Cross for the 2008 NASCAR Sprint Cup Season 2Health News:3M Donates Two Full Paint Schemes to American Red Cross for the 2008 NASCAR Sprint Cup Season 3Health News:WellPoint Executive Mark Boxer Recognized as One of Computerworld's 2008 Premier 100 IT Leaders 2Health News:WellPoint Executive Mark Boxer Recognized as One of Computerworld's 2008 Premier 100 IT Leaders 3Health News:Forever young: Differentiation blocked in tumor stem cells 2Health News:Emergency responders at high risk to miss work because of injuries 2Health News:Emergency responders at high risk to miss work because of injuries 3Health News:Parental Control of Eating Leads to Lighter Toddlers 2Health News:Parental Control of Eating Leads to Lighter Toddlers 3
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    Medicine Products: